NHS National Framework Agreement for the Supply of products for the management of Hereditary Angioedema

A Contract Award Notice
by NHS ENGLAND

Source
Find a Tender
Type
Framework (Goods)
Duration
not specified
Value
£1
Sector
HEALTH
Published
19 Jul 2022
Delivery
not specified
Deadline
n/a

Concepts

Location

United Kingdom: ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above

Geochart for 1 buyers and 14 suppliers

1 buyer

10 suppliers

Description

National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points. NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.Additional CPV Codes:33141520 – Plasma Extracts33141510 – Blood Products

Lot Division

1 C1 Esterase – Recombinant IV (acute treatment)
2 C1 Esterase – Plasma derived IV (acute treatment)
3 C1 Esterase – Plasma derived IV (prophylaxis treatment)
4 C1 Esterase – Plasma derived Subcut (prophylaxis treatment)
5 Icatibant
6 Lanadelumab
7 Berotralstat

Award Detail

1 Pharming Group (Darwinweg)
  • Hereditary Angioedema. Lot 1 - C1 Esterase – Recombinant IV (acute treatment)
  • Reference: 019699-2022-cm/phs/19/5583-1
  • Value: £1
2 Takeda (London)
  • Lot 3 - C1 Esterase – Plasma derived IV (prophylaxis treatment)
  • Reference: 019699-2022-cm/phs/19/5583-2
  • Value: £1
3 Takeda (London)
  • Hereditary Angioedema. Lot 6 - Lanadelumab
  • Reference: 019699-2022-cm/phs/19/5583-3
  • Value: £1
4 Biocryst Ireland (None)
  • Hereditary Angioedema. Lot 7 - Berotralstat
  • Reference: 019699-2022-cm/phs/19/5583-4
  • Value: £1
5 CSL Behring (Haywards Heath)
  • Hereditary Angioedema. Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
  • Reference: 019699-2022-cm/phs/19/5583-5
  • Value: £1
6 Takeda (London)
  • Hereditary Angioedema. Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
  • Reference: 019699-2022-cm/phs/19/5583-6
  • Value: £1
7 CSL Behring (Haywards Heath)
  • Lot 4 - C1 Esterase – Plasma derived Subcut (prophylaxis treatment)
  • Reference: 019699-2022-cm/phs/19/5583-7
  • Value: £1
8 Martindale Pharma (Wooburn Green)
  • Hereditary Angioedema. Lot 5 - Icatibant
  • Reference: 019699-2022-cm/phs/19/5583-8
  • Value: £1
9 Piramal Critical Care (West Drayton)
  • Hereditary Angioedema. Lot 5 - Icatibant
  • Reference: 019699-2022-cm/phs/19/5583-9
  • Value: £1
10 Wockhardt (Wrexham)
  • Hereditary Angioedema. Lot 5 - Icatibant
  • Reference: 019699-2022-cm/phs/19/5583-10
  • Value: £1
11 Cipla (Addlestone)
  • Hereditary Angioedema. Lot 5 - Icatibant
  • Reference: 019699-2022-cm/phs/19/5583-11
  • Value: £1
12 Takeda (London)
  • Hereditary Angioedema. Lot 5 - Icatibant
  • Reference: 019699-2022-cm/phs/19/5583-12
  • Value: £1
13 Accord (Barnstaple)
  • Hereditary Angioedema. Lot 5 - Icatibant
  • Reference: 019699-2022-cm/phs/19/5583-13
  • Value: £1
14 Celix Pharma (Middlesex)
  • Hereditary Angioedema. Lot 5 - Icatibant
  • Reference: 019699-2022-cm/phs/19/5583-14
  • Value: £1

Award Criteria

Security of Supply 20%
Ease of Use 10%
price 70%

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Options are available.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. **

Reference

Domains